Lipids form the backbone of our nanomedicine. Lipids are biomimetic, and therefore any risk of product or secondary clinical toxicity is minimised. The prodrugs in our nanomedicines are less toxic than the active drugs which form once the prodrugs enter cancer cells. 

NanoMed’s prodrugs are loaded within the membrane of the nanoparticle and are protected from degradation by a PEG coating on the outer surface of the nanoparticles. The products remaining after biodegradation of the nanoparticles are endogenous and biocompatible, and can be absorbed and/or excreted readily by the body.